You are here: Home » Health » News
Business Standard

Lab test to detect protective effects of Covid-19 antibodies developed

"Our assay could be used to tell whether antibodies have been developed in individuals who have had contacts with SARS-CoV-2," the researchers said in a paper published in the journal JCI Insight

Coronavirus | Coronavirus Tests

IANS  |  New York 

Coronavirus, vaccine, covid, drugs, clinical trials

Scientists have developed a new lab testing procedure for the detection of antibodies against SARS-CoV-2 that gives results more quickly than existing assays and specifically identifies so-called "neutralizing" antibodies - those that protect by blocking infection of cells.

"With many assays currently in use, we can detect antibodies, but that doesn't tell us if they're neutralizing antibodies. We only know the level of antibodies someone has," said study author Shan-Lu Liu from Ohio State University in the US.

"Some antibodies might be protective, some might not be protective, and some might even enhance infection - we know with this type of and some other viruses, some antibodies can even do harm," he said.

"Our assay examines whether antibodies are potentially protective, which means they prevent a patient from reinfection and block viral replication. That's the outcome of infection that we want people to have," Liu added.

In analyses of blood samples from several different populations that had tested positive for Covid-19, the researchers found with this new assay that, overall, ICU patients had produced the highest concentration of neutralizing antibodies, and convalescent plasma donors and health care workers had the lowest antibody levels.

"Our assay could be used to tell whether antibodies have been developed in individuals who have had contacts with SARS-CoV-2," the researchers said in a paper published in the journal JCI Insight.

For the results, the researchers developed what is called a "pseudotype" virus-neutralizing antibody assay, in which an HIV vector and core is coated with the SARS-CoV-2 spike protein to detect antibodies against the

The team applied a new approach by selecting a different form of the light-producing enzyme that can be detected conveniently in culture media containing the virus-infected cells.

That choice saved several steps, and time, in the detection process without losing accuracy and sensitivity to the target virus.

The results showed that, in general, hospitalised patients - and ICU patients in particular - had the highest concentrations, or titers, of neutralizing antibodies in their systems.

However, over 14 per cent of those who had been hospitalized had no or very low levels of antibodies.

The assay detected no SARS-CoV-2 antibodies in the samples from people who had been sick with other types of respiratory diseases.

The test accuracy was further validated by verifying in a lab setting that the antibodies detected in the Covid-19 patient blood samples did in fact neutralize the authentic SARS-CoV-2 virus.



(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, October 20 2020. 19:43 IST